Conference Day One

Wednesday 19th November 2025

8:00 am Check-In & Light Breakfast

8:50 am Chair’s Opening Remarks

  • Ruchi Shah Director, Drug Product, Vaccines Technical Research & Development, GSK US

Adopting Cryo-EM & SAXS to Elucidate LNP Stability & Delivery for More Effective Drug Products

9:00 am Enhancing LNP Morphology & Potency by Leveraging Cryo-EM to Improve LNP Delivery Performance

Synopsis

  • Finding a biological conclusion from Cryo-EM images to link them to LNP performance
  • Combining Cryo-EM with orthogonal approaches such as XRD to predict LNP efficacy
  • Uncovering how to interpret Cryo-EM images to correlate LNP formulation with morphology, potency and delivery

NEW DATA, NEW COMPANY

9:30 am Harnessing Cryo-EM & SAXS to Uncover LNP Structure & Enhance Stability for More Potent & Targeted LNP Drug Products

  • Dandan Ling Director, Formulation Research & Development, Suzhou Aibo Biotechnology Co., Ltd.

Synopsis

  • Leveraging imaging techniques to gain a deeper understanding of LNP internal structure and aligning this with delivery performance and potency
  • Implementing Cryo-EM and SAXS to dive deeper into LNP packing and arrangement
  • Derisking LNP products by utilizing Cryo-EM for process development and quality control

NEW DATA, NEW COMPANY

10:00 am Morning Break & Speed Networking

Synopsis

This session is your opportunity to meet face-to-face with some of the brightest minds working on

LNP characterization, and establish meaningful business and scientific relationships to build upon

throughout the conference

Advancing Understanding of LNP Physicohemical Properties by Harnessing Imaging Techniques for Greater Insights into LNP Size & Morphology

11:00 am Characterization of Lipid Nanoparticles Using Macro Mass Photometry: Insights into Size & Mass

  • Jikang Wu Senior Principal Scientist, Regeneron Pharmaceuticals

Synopsis

  • Macro mass photometry (MMP) was used for the first time to analyze the mass and size of lipid nanoparticles
  • MMP revealed the effects of PEG-lipid concentration, mRNA encapsulation, and antibody conjugation on LNP size and mass
  • The study demonstrated MMP’s utility in monitoring LNPs under various stress conditions

NEW DATA, NEW COMPANY

11:30 am Truly Orthogonal LNP Analytics: Insights from Spectradyne’s ARC Particle Analyzer

Synopsis

  • Look beyond light scattering and Cryo-TEM for LNP particle analysis
  • Spectradyne’s ARC particle analyzer offers a truly orthogonal approach
  • The ARC yields unique insights for LNP size, concentration, payload, and incorporation of targeting ligands

11:40 am Panel Discussion: Decoding LNP Function Through Advanced Imaging to Enhance Therapeutic Design & Endosomal Escape

  • Kan Zhu Director, Head of Analytical Biochemistry, CSL
  • Zack Zhang Director - Analytical Development, Beam Therapeutics Inc.
  • Wei-Chiang Chen Associate Director, Sanofi

Synopsis

  • How to gain robust and reliable biological conclusions from imaging analysis?
  • How to orthogonally apply imaging methods for accurate characterization of lipid arrangement and link to performance?
  • How does the LNP morphology impact its endosomal escape profile?

Enhancing Analytical Strategies for Decoding Encapsulation Efficiency to Improve LNP Drug Safety & Potency

12:30 pm Lunch & Networking

1:20 pm Post-Loading Lipid Nanoparticles: A Feasible Route for RNA Delivery

  • Navid Bizmark Materials Characterization Team Lead – Senior Principal Scientist, Pfizer

Synopsis

  • How turbulent mixers can be used to generate stable empty and RNA-loaded LNPs
  • A route to post-load empty LNPs with RNAs of different payloads with similar (if not better) in vitro efficacy compared to conventional co-loaded LNPs
  • The rationale behind the performance of co-loaded and post-loaded LNPs

NEW COMPANY, NEW DATA

1:50 pm Session Details to be Revealed: Nanofcm

2:05 pm Optimizing Dual-Cargo Delivery: Advanced Characterization Techniques for Gene Editing with Lipid Nanoparticles

Synopsis

  • Lipid nanoparticle-based gene therapies require the delivery of multiple nucleic acid cargoes (e.g., Cas9 mRNA and guide RNA). The identification of the optimal ratio of mRNA to guide RNA will be discussed
  • New advanced characterization strategies to quantify dual-cargo encapsulation via direct injection using SEC-HPLC will be proposed for routine analysis
  • Orthogonal methods for assessing LNP packing and morphology, as well as their correlation to in vivo activity, will be examined

NEW DATA

2:35 pm Afternoon Networking Break & Scientific Poster Session

Synopsis

As analytical development for LNP drug products continue to progress from strength to

strength, it is more important than ever to collaborate and learn with your peers. Join

this dedicated session to share your latest data and have the first look on what your

peers are working on!

Expanding LNP Therapeutic Reach by Optimizing Analysis of Targeted LNPs for Extrahepatic Delivery

3:30 pm Mobilize: A Modular & Versatile Targeted LNP Delivery Platform for Extra- Hepatic RNA Therapeutics

Synopsis

  • Harnessing surface functionalization strategies for LNPs to achieve targeted delivery of RNA therapeutics
  • Developing advanced assays to characterize the surface functionalization process
  • Delving into physicochemical characterization strategies to assess particle size and encapsulation efficiency of targeted LNPs for RNA medicines

NEW DATA, NEW COMPANY

4:00 pm Roundtable Discussion: Evaluating Targeted LNP Stability to Improve Shelf-Life & Functionality for More Durable & Effective Medicines

Synopsis

  • How does conjugation chemistry, linker types and formulation conditions impact targeting ligand stability?
  • Unravelling analytical strategies to assess ligand stability and the mechanisms ofligand detachment in biological environmentsHow to maintain shelf-life and ligand activity on targ
  • ted LNPs over time?

4:30 pm Analyzing In Vivo Delivery of RNA by Targeted Lipid Nanoparticles (tLNP) to Hematopoietic Stem Cells & T-cells in Humanized Mice & Non-Human Primates

  • Mohit Gupta Principal Scientist, Tessera Therapeutics

Synopsis

  • Delving into strategies for characterizing in vivo RNA extrahepatic delivery with tLNPs
  • Evaluating approaches to conjugate and analyze targeting ligands on LNPs for specific delivery
  • Leveraging this analysis to find LNP compositions optimized for efficacy and tolerability

5:00 pm Chair’s Closing Remarks & End of Conference Day One

  • Ruchi Shah Director, Drug Product, Vaccines Technical Research & Development, GSK US